Results 131 to 140 of about 14,322 (328)

Ginsenoside Rb1 Improves Post-Cardiac Arrest Myocardial Stunning and Cerebral Outcomes by Regulating the Keap1/Nrf2 Pathway. [PDF]

Int J Mol Sci, 2023
Chen L, Geng N, Chen T, Xiao Q, Zhang H, Huo H, Jiang L, Shao Q, He B.   +8 more
europepmc   +1 more source

Use of aromatic hydroxylation of phenylalanine to measure production of hydroxyl radicals after myocardial ischemia in vivo. Direct evidence for a pathogenetic role of the hydroxyl radical in myocardial stunning. [PDF]

, 1993
Jun Sun, Harsimran Kaur, Barry Halliwell, X Y Li, Roberto Bolli   +4 more
openalex   +1 more source

Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review

ESC Heart Failure, EarlyView.
Abstract Chronic kidney disease (CKD) and chronic heart failure (HF) frequently coexist and, when comorbid, are associated with poorer outcomes. These two diseases have common risk factors, such as diabetes, obesity and hypertension, and common pathophysiological connected mechanisms, including inflammation, endothelial dysfunction, neurohormonal ...
Johann Bauersachs, Eri Toda Kato, Janani Rangaswami   +2 more
wiley   +1 more source

Reperfusing the myocardium - a damocles Sword

Indian Heart Journal, 2018
Return of blood flow after periodic ischemia is often accompanied by myocardial injury, commonly known as lethal reperfusion injury (RI). Experimental studies have shown that 50% of muscle die of ischemia and another 50% die because of reperfusion. It is
V.K. Shah, K.K. Shalia
doaj  

Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. [PDF]

, 1996
Jun Sun, Xiufeng Tang, S W Park, Yumin Qiu, Julio F. Turrens, Roberto Bolli   +5 more
openalex   +1 more source

Angiotensin receptor‐neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure

ESC Heart Failure, EarlyView.
Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung, Dong‐Hyuk Cho, Jimi Choi, Mi‐Na Kim, Chan Joo Lee, Jung‐Woo Son, Yaeni Kim, Jong‐Chan Youn, Byung‐Su Yoo   +8 more
wiley   +1 more source

Association of baseline and longitudinal changes in insulin‐like growth factor‐binding protein‐7 with the risk of incident heart failure: Data from the PREVEND study

European Journal of Heart Failure, EarlyView.
Insulin‐like growth factor‐binding protein‐7 (IGFBP7) and heart failure (HF) risk: the PREVEND study. CI, confidence interval; HR, hazard ratio. Abstract Aim Senescence is a major risk factor for heart failure (HF), and insulin‐like growth factor‐binding protein‐7 (IGFBP7) has been identified as an important senescence‐inducing factor.
Sabrina Abou Kamar, Valentina Bracun, Maissa El‐Qendouci, Nils Bomer, Stephan J.L. Bakker, Ron T. Gansevoort, Eric Boersma, Isabella Kardys, Rudolf A. de Boer, Navin Suthahar   +9 more
wiley   +1 more source

Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Abstract Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices
Biykem Bozkurt, Wilfried Mullens, Christophe Leclercq, Andrea M. Russo, Gianluigi Savarese, Michael Böhm, Loreena Hill, Koichiro Kinugawa, Naoki Sato, William T. Abraham, Antoni Bayes‐Genis, Alexandre Mebazaa, Giuseppe M.C. Rosano, Shelley Zieroth, Cecilia Linde, Javed Butler   +15 more
wiley   +1 more source

Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death across cardio‐kidney‐metabolic diseases: A meta‐analysis of randomized clinical trials

European Journal of Heart Failure, EarlyView.
Abstract Aims Sudden cardiac death (SCD) is a prevalent cause of mortality among patients with cardio‐kidney‐metabolic (CKM) diseases. Mineralocorticoid receptor antagonists (MRAs) reduce the risk of SCD in patients with left ventricular dysfunction, but it is unclear if similar effects are expected across different CKM risk populations irrespective of
Pedro Marques, Faiez Zannad, João Pedro Ferreira   +2 more
wiley   +1 more source

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +16 more
wiley   +1 more source